Amble Health vs IVIM Health vs MEDVi (2026)
On tirzepatide, the order is IVIM Health↗ ($278) → Amble Health ($300) → MEDVi↗ ($399) — gaps of $22 and then $99 a month, a $1,452 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three records, one screen
IVIM Health: the record, condensed
On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Note the shape: $208 is the number in the marketing, $278 is the number at maintenance. The $70 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.
The all-in figure already contains a compulsory $75 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $203 would be exactly that kind of mirage.
Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.
On semaglutide, the number that matters at IVIM Health is $149 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.
Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.
To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.
Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗
Amble Health: the record, condensed
Amble Health’s tirzepatide program bills $300 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $300 is the whole subscription, which makes Amble Health unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #9 of 17 in the verified tirzepatide index — $85/month above the floor (NexLife, $215) — and sits $149 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,600.
Operationally at Amble Health: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Amble Health page
MEDVi: the record, condensed
Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.
To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.
On semaglutide, the number that matters at MEDVi is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.
Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗
Prices, gaps, and what sits inside them
IVIM Health holds the low ground at $278 (its $75 membership already inside). Amble Health follows at $300 (+$22/mo, $264/yr). MEDVi tops the trio at $399 (+$121/mo over the leader, $1,452/yr) — note its record’s watch-out below.
The semaglutide picture reshuffles nothing: IVIM Health $149 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.
Who wins what
Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): Amble Health and MEDVi; dose-flat structure: Amble Health and MEDVi; cheapest semaglutide of the three: IVIM Health ($149).
Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs Amble Health (record · record) · IVIM Health vs MEDVi · Amble Health vs MEDVi (record · record).
Everything besides the three prices
Memberships: IVIM Health $75/mo (inside its figure); Amble Health none; MEDVi none. Structures: IVIM Health step/tiered; Amble Health dose-flat; MEDVi dose-flat. Pharmacies: IVIM Health not named; Amble Health not named; MEDVi not named. States: IVIM Health — not published; Amble Health — not published; MEDVi — priced differently in CA/NC on some plans. Exit terms: IVIM Health — membership mandatory; Amble Health — not published; MEDVi — 12-month plan applies to lowest rate.
The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); Amble Health third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).
The trio on semaglutide, across time
3 mo: IVIM Health $447 vs MEDVi $897 6 mo: IVIM Health $894 vs MEDVi $1,794 12 mo: IVIM Health $1,788 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.
The trio, annualized
IVIM Health: $3,336/yr monthly-billed; Amble Health: $3,600/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,904 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.
The elimination read
Work it as eliminations rather than a beauty contest. MEDVi enters owing an explanation: $121/month above IVIM Health compounds to $1,452 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Amble Health survives the first cut only to face the harder question — whether its dose-flat structure removes titration repricing is worth $22 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. IVIM Health is what remains: the arithmetic answer at $278, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.
The same trio on best published rate: IVIM Health $278 → Amble Health $300 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, Amble Health $900, MEDVi $1,197; 6 months — IVIM Health $1,668, Amble Health $1,800, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.
Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): IVIM Health 4/5 · Amble Health 3/5 · MEDVi 4/5. The gap between IVIM Health (4/5) and Amble Health (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.
The three-way verdict compresses cleanly: IVIM Health is the default on arithmetic; Amble Health earns the middle only where its structure (flat pricing) solves something the floor does not; and MEDVi’s $121/month premium over the leader — $1,452 a year, roughly 5.2 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.
Frequently asked
Which is cheapest: Amble Health, IVIM Health, or MEDVi?
IVIM Health, at $278/month all-in tirzepatide — $22 under Amble Health and $121 under MEDVi; on semaglutide the cheapest of the three is IVIM Health at $149. Captured 2026-08-09.
Which of the three is best over a full year?
IVIM Health’s best path prices twelve months at $3,336; monthly-billed years run IVIM Health $3,336, Amble Health $3,600, MEDVi $4,788.
Are these rankings paid or editorial?
Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.